Venture Fund Vii, L.P.Arch ... Net Worth

The estimated Net Worth of Venture Fund Vii, L.P.Arch ... is at least $9.75 Million dollars as of 15 July 2019. Venture Arch owns over 63,000 units of Syros Pharmaceuticals stock worth over $6,829,702 and over the last 7 years Venture sold SYRS stock worth over $2,920,223.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture Arch SYRS stock SEC Form 4 insiders trading

Venture has made over 3 trades of the Syros Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently Venture sold 63,000 units of SYRS stock worth $489,510 on 15 July 2019.

The largest trade Venture's ever made was selling 167,503 units of Syros Pharmaceuticals stock on 12 March 2019 worth over $1,311,548. On average, Venture trades about 98,772 units every 32 days since 2018. As of 15 July 2019 Venture still owns at least 4,242,051 units of Syros Pharmaceuticals stock.

You can see the complete history of Venture Arch stock trades at the bottom of the page.

Insiders trading at Syros Pharmaceuticals

Over the last 8 years, insiders at Syros Pharmaceuticals have traded over $8,259,551 worth of Syros Pharmaceuticals stock and bought 5,052,185 units worth $51,830,966 . The most active insiders traders include Group, Llc Green Jeremy Red..., Srinivas Akkaraju, and Stephane Bancel. On average, Syros Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $135,148. The most recent stock trade was executed by Richard A Young on 28 June 2024, trading 34,837 units of SYRS stock currently worth $178,365.

What does Syros Pharmaceuticals do?

syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Complete history of Venture Arch stock trades at Pulmatrix Inc and Syros Pharmaceuticals

Syros Pharmaceuticals executives and stock owners

Syros Pharmaceuticals executives and other stock owners filed with the SEC include:

• Nancy Simonian,
  President, Chief Executive Officer, Director
• Joseph Ferra,
  Chief Financial Officer
• Jeremy Springhorn,
  Chief Business Officer
• David Roth,
  Chief Medical Officer
• Eric Olson,
  Chief Scientific Officer
• Gerald Quirk,
  Chief Legal & Administrative Officer
• Dr. Nancy A. Simonian M.D.,
  Pres, CEO & Director
• Dr. David A. Roth,
  Chief Medical Officer
• Dr. Eric R. Olson,
  Chief Scientific Officer
• Richard Young,
  Director
• Dr. Richard A. Young Ph.D.,
  Scientific Founder, Member of Scientific Advisory Board & Director
• Mark Alles,
  Independent Director
• Peter Wirth,
  Independent Chairman of the Board
• Marsha Fanucci,
  Independent Director
• Amir Nashat,
  Independent Director
• Phillip Sharp,
  Independent Director
• Srinivas Akkaraju,
  Independent Director
• Hannah Deresiewicz,
  IR Contact Officer
• S. Gail Eckhardt,
  Director
• Dr. Christian C. Fritz Ph.D.,
  Head of Biology
• Naomi Aoki,
  VP of Corp. Communications & Investor Relations
• Gerald E. Quirk,
  Chief Operations Officer & Sec.
• Jason Haas,
  Chief Financial Officer
• Dr. Nathanael S. Gray Ph.D.,
  Scientific Founder & Member of Scientific Advisory Board
• Dr. James E. Bradner M.D.,
  Founder
• Alice Tsang Shaw,
  Director
• Ventures Fund Iv, L.P.Flags...,
  
• Sanj K Patel,
  Director
• Vicki L Sato,
  Director
• Michael W Bonney,
  Director
• Colleen Elizabeth De Simone,
  Principal Accounting Officer
• Robert Nelsen,
  Director
• Venture Fund Vii, L.P.Arch ...,
  
• Kyle D. Kuvalanka,
  Chief Operating Officer
• Stephane Bancel,
  Director
• Management Co. Vii, L.L.C.P...,
  
• Pharm Tech Healthcare Fund ...,
  10% owner
• Group, Llc Green Jeremy Red...,
  
• Venture Fund Vii Lparch Ven...,
  
• Healthcare Ventures Ii, L.P...,
  10% owner
• James E Deerfield Mgmt L.P....,
  
• Kristin Stephens,
  Chief Development Officer
• Deborah Dunsire,
  
• Jason Haas,
  Chief Financial Officer
• Timothy Tyson,
  
• Conley Chee,
  President & CEO
• Andrew M. Oh,